Clinical Trial Update: Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating whether adding tazemetostat to dabrafenib and trametinib improves outcomes in patients with metastatic melanoma that progressed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)
• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING